Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Amyotrophic Lateral Sclerosis.
Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis.
Team Gleason and Synchron Expand Collaboration to Drive Awareness of The Synchron BCI Community to Advance Brain Computer Interface Technology ...
Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...
A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...
The Vermont Department of Health recently released data from the state's first registry for the disease Amyotrophic Lateral ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Chinese startup NeuroXess on Thursday reported two significant clinical-trial milestones its flexible brain-computer interface BCI device successfu ...
Petit Chef on MSN1d
Hidden secret behind neurodegenerative diseases revealed: your fork may be the key!Neurodegenerative diseases pose a serious threat to public health, with an increasing impact among the elderly population.
Interesting Engineering on MSN5d
Brain-computer interface developed in China decodes thought real-timeChinese startup NeuroXess' new BCI can decipher the complex Chinese language in brain, operate a robotic arm and interact with AI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback